Astex
  • Discover Astex
    • Our Mission & Values
    • Our Leadership Team
      • UK – Discovery Research
        • Jeremy Carmichael
        • Harren Jhoti
        • Michelle Jones
        • Neil Jones
        • John Lyons
        • Chris Murray
        • David Rees
        • Nicola Wallis
        • Nicola Wilsher
      • USA – Product Development
        • Mohammad Azab
        • Martin Buckland
        • Harold N. Keer
        • Nipun Davar
        • Yong Hao
        • Joseph Iovino
        • Samuel Jason
        • Shinichi Sato
        • Nancy Worrell
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Proprietary Products and Programs
        • Guadecitabine (SGI-110) DNMT inhibitor (Hematological Malignancies and Solid Tumors)
        • ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX727 Oral DNMT inhibitor (Hematological Malignancies)
        • ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • AZD5363 PKB/Akt Inhibitor (Oncology)
        • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation
  • Partnering
  • Our People
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Astex in the News
  • Contact
  • Search
  • Menu
You are here: Home / 2009 / Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe

Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe

23 November 2009/in 2009, News /by webadmin

Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe

/wp-content/uploads/2019/11/logo_white.png 0 0 webadmin /wp-content/uploads/2019/11/logo_white.png webadmin2009-11-23 12:33:002016-11-28 12:33:21Astex Granted Orphan Drug Status for AT9283 in AML in USA and Europe

Copyright © Astex Pharmaceuticals
All rights reserved

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal

Member of the Otsuka Group

SuperGen Appoints David Bearss, Ph.D., Chief Scientific Officer 2009 AACR: ID of Predicted Biologically Effective Dose of AT7519 in Phase 1...
Scroll to top
By continuing to use this website you will be agreeing to our Terms & Conditions, our Privacy Policy, and the use of cookies.continue